These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1135 related items for PubMed ID: 12668699

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

  • 4. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 12; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 8. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
    Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC.
    N Engl J Med; 1995 Dec 21; 333(25):1670-6. PubMed ID: 7477219
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):425-31. PubMed ID: 16053953
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep 02; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 11. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J, Gerber RA, Roberts C, Gheorghiade M.
    Am J Ther; 2010 Sep 02; 17(5):446-54. PubMed ID: 20844344
    [Abstract] [Full Text] [Related]

  • 12. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 02; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct 30; 145(44):42-3. PubMed ID: 14655506
    [No Abstract] [Full Text] [Related]

  • 15. Eplerenone reduces morbidity and mortality after acute MI.
    Cardiovasc J S Afr; 2006 Oct 30; 17(5):280. PubMed ID: 17117244
    [No Abstract] [Full Text] [Related]

  • 16. Review article: eplerenone: an underused medication?
    Abuannadi M, O'Keefe JH.
    J Cardiovasc Pharmacol Ther; 2010 Dec 30; 15(4):318-25. PubMed ID: 20876342
    [Abstract] [Full Text] [Related]

  • 17. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.
    J Card Fail; 2012 Apr 30; 18(4):265-81. PubMed ID: 22464767
    [Abstract] [Full Text] [Related]

  • 18. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 19. Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
    Ukena C, Dobre D, Mahfoud F, Kindermann I, Lamiral Z, Tala S, Rossignol P, Turgonyi E, Pitt B, Böhm M, Zannad F.
    J Card Fail; 2012 Jun 01; 18(6):439-45. PubMed ID: 22633301
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 01; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.